Brief: NLS Pharmaceutics On Aug 28, Agreed With Eurofarma Laboriatorios S.A. To Terminate EF License Agreement Dated Feb 2019, Effective Sept 30
Brief: NLS Pharma Says Co and Kadimastem Announce Binding Term Sheet to Merge
Brief: NLS Pharmaceutics Says Nasdaq Panel Grants NLS Pharmaceutics' Request For Extension To Comply With Continued Listing Requirements
Brief: NLS Pharmaceutics Says On May 16 Co Entered Into Additional Bridge Loan Addendums To Bridge Loan Agreement Dated Nov 15, 2023
Brief: Nls Pharmaceutics Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request Hearing
U.S. STOCKS ON THE MOVE-Intel, Taysha Gene Therapies, General Mills
Brief: Nls Pharmaceutics AG Exclusive Option Agreement To Develop And Commercialize Next Generation Dual Orexin Agonist Platform Of Aexon Labs, Inc
NLS Pharmaceutics falls after cutting 50% of workforce
Brief: Nls Pharmaceutics AG Announces Selection Of Strategic Partner And Securing A Bridge Loan
Brief: NLS Pharmaceutics Says Elena Thyen-Pighin Has Been Appointed As Its CFO
RCS - NLS Pharmaceutics AG - NLS Pharmaceutics Announces an R&D Update Webcast
NLS Pharmaceutics rises on patent for its drug for ADHD treatment in Hong Kong
Brief: Nls Pharmaceutics Announces Israeli Patent Grant Covering Mazindol For Treatment Of Attention Deficit Hyperactivity Disorder And Other Sleep Disorders Through 2037
RCS - NLS Pharmaceutics AG - NLS Pharmaceutics Announces Closing of Initial
RCS - NLS Pharmaceutics AG - NLS Pharmaceutics Announces Purchase Agreement
Brief: NLS Pharmaceutics Ltd Files Prospectus To The Resale, From Time To Time, By The Selling Shareholders Of Up To 11.9 Mln Common Shares - SEC Filing
RCS - NLS Pharmaceutics AG - NLS Pharmaceutics Announces Launch of Program
U.S. STOCKS ON THE MOVE-Spirit Airlines Inc, Tesla Inc, Kellogg
Brief: Nls Pharmaceutics AG Announces Positive Interim Top-Line Data For Quilience (Mazindol Er) In Patients With Narcolepsy